Zdrowie i gospodarka · 14/03/2011
FDA Releases Revised Draft Guidance on User Fee Waivers for Drug and Biological Products
The Food and Drug Administration (FDA) has made available a revised draft guidance for industry on user fee waivers, reductions, and refunds for drug and biological products, providing recommendations for applicants considering fee waiver or reduction requests.
Source: Federal Register — Health and Human ServicesOpen original release →